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Abstract
Background: The Coping with Persistent Pain, Effectiveness Research into Self-management (COPERS) trial assessed
whether a group-based self-management course is effective in reducing pain-related disability in participants with
chronic musculoskeletal pain. This article describes the statistical analysis plan for the COPERS trial.
Methods and design: COPERS was a pragmatic, multicentre, unmasked, parallel group, randomised controlled trial.
This article describes (a) the overall analysis principles (including which participants will be included in each
analysis, how results will be presented, which covariates will be adjusted for, and how we will account for
clustering in the intervention group); (b) the primary and secondary outcomes, and how each outcome will be
analysed; (c) sensitivity analyses; (d) subgroup analyses; and (e) adherence-adjusted analyses.
Trial registration: ISRCTN24426731
Keywords: Statistical analysis plan, Randomised controlled trial, Self-management, Chronic musculoskeletal pain,
Complex intervention
Update
Background
COPERS (Coping with Persistent Pain, Effectiveness
Research into Self-management) was a pragmatic, multi-
centre, unmasked, parallel group, randomised controlled
trial [1]. The protocol for the COPERS trial has been
published previously [1] and gives details on the rational
for the trial, the intervention and control groups, the
inclusion/exclusion criteria, and the sample size calcula-
tion. Briefly, the main aim of the COPERS trial was to
assess whether a group-based learning course was effect-
ive in reducing pain-related disability in participants
with chronic musculoskeletal pain [2]. The intervention
was a 3-day training course. Course content is shown in
Table 1, and the schedule of assessments is shown in
Figure 1. The intervention was compared with usual care
plus a relaxation CD and pain education leaflet. In this
article, we describe the statistical analysis plan, which
outlines how data analysis for the COPERS trial will be
performed.
The statistical analysis plan was finalised and approved
on 3 October 2013. All trial investigators were blinded to
patient outcomes broken down by treatment group until
after the analysis plan was signed off and the database was
locked. Participant recruitment began in August 2011 and
finished in July 2012 (participant follow-up was completed
in August 2013). The trial database was locked after the
statistical analysis plan was approved. Data analysis did not
begin until after the analysis plan was approved, and after
the database was locked.
The original sample size calculation called for 685 par-
ticipants (391 in the intervention group and 294 in the
control group, to be randomised in a 4:3 ratio). However,
we required a sufficient number of participants in each
group-based learning course to make the intervention
viable; therefore, we continued recruitment until there was
an adequate number of participants for each course. This
led to 703 participants (403 intervention, 300 control).
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Ethics approval was granted by Cambridgeshire Ethics
11/EE/04. All patients provided written informed consent
prior to randomisation.
Outcomes
Primary outcome
The primary outcome was the pain-related disability score
(which is a subscale of the Chronic Pain Grade question-
naire (CPG disability) [3]) at 12 months post-randomisation.
The three questions in this subscale assess the extent to
which the participant’s pain has, in the previous 6 months:
(i) interfered with their ability to perform their daily activ-
ities; (ii) changed their ability to take part in recreational,
social, and family activities; and (iii) changed their ability
to work. Each of the three questions is rated on a scale of
0 to 10, with 0 reflecting no change or interference, and
10 reflecting extreme change or interference.
The primary outcome is the mean of these three ques-
tions, multiplied by 10; that is, if X1, X2, and X3 repre-
sent the three questions, and Y represents the primary
outcome, then:
Y ¼ 10 X1þ X2þ X3ð Þ=3
The primary outcome is therefore recorded on a scale
from 0 to 100, with higher scores reflecting larger inter-
ference or change in the participant’s ability to perform
daily activities, work, or take part in recreational, social,
and family activities.
Secondary outcomes
The secondary outcomes are:
1. CPG disability at 6 months post-randomisation [3]
2. CPG pain intensity score at 6 and 12 months post-
randomisation [3]
3. Pain Self-Efficacy Questionnaire (PSEQ) score at 6
and 12 months post-randomisation [4]
4. Hospital Anxiety and Depression Scale (HADS) Anxiety
score at 6 and 12 months post-randomisation [5]
5. Hospital Anxiety and Depression Scale (HADS)
Depression score at 6 and 12 months post-
randomisation [5]
6. Chronic Pain Acceptance Questionnaire (CPAQ)
score at 6 and 12 months post-randomisation [6]
7. Health Education Impact Questionnaire (HEIQ)
Social integration score at 6 and 12 months post-
randomisation [7]
8. EQ-5D at 6 and 12 months post-randomisation [8]
9. Census global health question at 6 and 12 months
post-randomisation [9]
10. Total Defined Daily Doses (Total DDD) of
psychotropic drugs consumed up to 12 months
post-randomisation
11. Total DDD of analgesics (including all opioids and
other central nervous system drugs) consumed for
pain up to 12 months post-randomisation
12. Total DDD of weak opioids consumed up to 12
months post-randomisation
13. Total DDD of strong opioids consumed up to 12
months post-randomisation
14. Proportion of participants using weak opioids at 12
months post-randomisation (defined as having
received a prescription for a weak opioid up to
twelve weeks before the 12-month follow-up date)
15. Proportion of participants using strong opioids at
12 months post-randomisation (defined as having
received a prescription for a strong opioid up to
twelve weeks before the 12-month follow-up date)
A guide to how outcomes are derived is available in
Additional file 1.
Analysis principles
General analysis principles
The main analysis for each outcome will use intention-
to-treat (ITT) principles, meaning that all participants
with a recorded outcome will be included in the analysis,
and will be analysed according to the treatment group to
which they were randomised [10]. More information on
which participants will be included in each analysis is
Table 1 The Coping with Persistent Pain, Effectiveness
Research into Self-management (COPERS) course content
overview
Day (10.00 am to 2.45 pm) Modules
Day 1 Introduction and understanding pain
and acceptance
Living and dealing with pain
Lunch
Activity: Art
Mind, mood and pain
Movement and posture, and Relaxation
Day 2 Dealing with unhelpful, negative
thoughts and barriers to change
Doing something about your
life with pain Lunch
Activity: Hand massage
Making pain more manageable
Movement and Relaxation
Day 3 Communication skills
Communication and
relationships
Lunch
Activity: Volunteering
Movement and Relaxation
Day 4 The future
Follow-up (2 weeks later,
10.00 am to 12.00)
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available in later sections. All P values will be two sided,
and the significance level is set at 5%.
Analyses for all outcomes will be presented as:
1. The number of participants included in the analysis,
by treatment group;
2. A summary measure of the outcome, by treatment
group (for example, mean (SD) for continuous
outcomes, number (%) for binary outcomes). Only
participants with a completely recorded outcome
will be used to calculate the summary measure
(for example, participants who complete only one of
three components of the CPG disability score will
not be included in the calculation of the summary
measure, although they will be included in estimated
the treatment through the use of multiple
imputation - see later sections);
3. A treatment effect, with a 95% confidence interval;
4. A two-sided P value.
All analyses will account for clustering by course in
the intervention group. This is because when the inter-
vention is delivered in clusters (for example, in a group
setting, or when the same therapist treats multiple
patients) it is necessary to account for the clustering in
the analysis to avoid increasing the type I error rate
[11-13]. Participants in the control group (who do not
attend courses), will act as their own cluster (that is,
each participant in the control group will belong to a
‘course’ where they are the only member).
Site of recruitment (London or Midlands) [14-17], age,
gender, and the HADS depression score at baseline will
be included as covariates in each analysis [17-20]. Add-
itionally, for continuous outcomes (CPG disability, CPG
pain intensity, PSEQ, HADS Anxiety, HADS Depression,
CPAQ, HEIQ, and EQ-5D), the outcome measured at base-
line will be included in the analysis [19]. Site of recruitment
will be adjusted for because it was used as a stratification
factor in the randomisation process, and therefore, it is ne-
cessary to include it in the analysis to maintain correct type
I error rates [11,14-16]. The other covariates will be in-
cluded in the analysis because adjustment for prognostic
factors can substantially increase power [17-21].
Continuous covariates (age, HADS depression score,
outcome measured at baseline) will be analysed using a
linear relationship with the outcome, as categorising
continuous covariates has been shown to lead to poor
performance in other scenarios [22]. We made the decision
Baseline questionnaire*
Demographics, CPG, HADS, EQ-5D, PSEQ, CPAQ, HEIQ (Social integration), Global health 
Question. 
Randomisation to:
Intervention: COPERS course plus usual care or 
Control: usual care, self guided relaxation and pain education leaflet 
12 weeks questionnaire*
PSEQ: self-efficacy 
6 month follow-up questionnaire*
CPG, HADS, EQ-5D, PSEQ, CPAQ, HEIQ (Social integration), Global health Question, non-
NHS health care resource use 
12 month follow-up questionnaire*
CPG, HADS, EQ-5D, PSEQ, CPAQ, HEIQ (Social integration), Global health Question, non-
NHS health care resource use 
Figure 1 Schedule of assessment. CPG, Chronic Pain Grade (Von Korff [3]); HADS, Hospital Anxiety and Depression Scale (Zigmond and Snaith
[5]); EQ-5D, Quality of life (EuroQol.org); PSEQ, Pain Self-Efficacy Questionnaire (Nicholas 1989, [4]); CPAQ, Chronic Pain Acceptance Questionnaire
(McCracken [6]); HEIQ, Social integration [7]; Census global health question (ons.gov.uk/census/2011-census).
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to assume a linear relationship prior to examining the ob-
served association between covariate and outcome in the
trial data, as previous research has shown that choosing
the analysis method based on study data can lead to biased
treatment effect estimates and incorrect type I error rates
in some scenarios [23-27].
Analysis of primary outcome
The primary outcome (CPG disability at 12 months) will
be analysed using a mixed-effects linear regression
model, with a ‘group-based learning course’ as a random
effect. Restricted maximum likelihood (REML) will be
used. The model will include site of recruitment, age,
gender, HADS depression score, and CPG disability at
baseline as covariates.
All participants who completed at least one of the
three questions that form the CPG disability score at
either 6 or 12 months will be included in the analysis.
Participants who did not fill out any portion of the CPG
disability score at both 6 or 12 months will be excluded
from the analysis.
Multiple imputation (MI) [28] will be used to account
for participants who have an observed outcome at 6
months, but are missing the outcome at 12 months, as
well as for participants who completed some, but not all,
of the questions on the CPG disability score at 12
months. A total of 20 imputations will be performed,
and results will be combined using Rubin’s Rules [28].
Only participants included in the analysis will be in-
cluded in the imputation model. The imputation model
will include the three questions that form the CPG dis-
ability score at baseline, 6 months, and 12 months, as
well as the site of recruitment, age, gender, the HADS
depression score at baseline, and employment status
(employed or in full-time education versus not employed
or in full-time education) (14 variables in total). We
chose to include these variables in the imputation model
because they will be included in the analysis model
(CPG disability score at baseline, 6 months, and 12
months, site of recruitment, age, gender, and HADS
depression score at baseline) or because we felt they
may be predictive of missingness (employed or in full-
time education versus not employed or in full-time
education). Imputation will be performed separately
within each treatment group [29]. In the intervention
group, multilevel imputation will be performed, with
‘course’ included in the imputation model as a random
effect [30,31].
Missing data in any of the covariates to be adjusted for
in the analysis (site of recruitment, age, gender, HADS
depression score, CPG disability and baseline) will be
accounted for at the same time as missing data in the
CPG disability score at 6 or 12 months, as these vari-
ables will be included in the same imputation model.
Sensitivity analyses for primary outcome
Method of accounting for missing data
We will perform three sensitivity analyses for the pri-
mary outcome to assess the robustness of the results to
other methods of account for missing data [32]. The first
sensitivity analysis involves specifying a different imput-
ation model than that used in the primary analysis, and
the last two sensitivity analyses involve the re-analysis of
the primary outcome using two approaches which are
not based on MI.
The sensitivity analyses are:
1. We will determine which baseline covariates are
associated with loss to follow-up and include them
in the imputation model. The analysis model will be
the same as that for the primary analysis, except for
the inclusion of additional covariates (that is, those
that we determined were associated with loss to
follow-up) in the imputation model.
2. We will perform a complete case analysis, where
all participants who did not complete all
components of the CPG disability score at 12
months will be excluded from the analysis. The
analysis model will be the same as that for the
primary analysis, except missing baseline
covariates will be replaced using mean imputation.
We used mean imputation as it has been shown
to give unbiased estimates and standard errors for
the treatment effect in randomised trials, and will
suffer only a small loss in efficiency when the
amount of missing data is small [33].
3. We will analyse the three components that form the
CPG disability score at 12 months, rather than the
overall CPG disability score. This will be done by
performing a multivariate analysis, where each of
the three components from the 12-month score are
included in the model as outcomes (that is, each
participant will have three outcomes). A three-level
mixed-effects model will be used, with random
effects for ‘course’ and for participant. Treatment-
by-question interactions will be included, allowing
the treatment effect to vary for each of the three
components. An overall treatment effect for CPG
disability at 12 months will be estimated using the
lincom function in Stata (StataCorp, College Station,
TX, USA) to combine the treatment estimates from
the three separate components. As above, missing
baseline covariates will be replaced using mean
imputation.
Participants with no completed follow-ups
The primary analysis has assumed that the excluded par-
ticipants (those not completing any questions on the
CPG disability questionnaire at both 6 and 12 months)
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were missing-at-random (that is, they were missing based
on the covariates included in the analysis model). To assess
the robustness to departures from this assumption, the
primary outcome will be assessed under a range of
missing-not-at-random scenarios. This will be done using
the formula
Δ ¼ Δprimary þ Y1P1−Y2P2
where Δ is the treatment effect under the missing-not-
at-random scenario, Δprimary is the treatment effect from
the primary analysis, Y1 and Y2 are the assumed mean
responses for participants with missing data in treatment
groups 1 and 2 respectively, and P1 and P2 are the pro-
portion of participants who were excluded from the ana-
lysis in groups 1 and 2, respectively. The standard error
for Δ is assumed to be approximately equal to the stand-
ard error for Δprimary. Y2 will be varied between 10, 25,
50, 75, and 90, and for each value of Y2, Y1 will be set to
Y2 - 10, Y2, and Y2 + 10. For example, for Y2 = 25, Y1 will
vary between 15, 25, and 35.
Re-definition of primary endpoint
The primary outcome is a composite of three questions.
The first question (Q1) assesses to what extent the
participant’s pain has interfered with daily activities in
the previous 6 months. This is assessed on a scale of
0 to 10, with higher scores indicating more interfer-
ence. The last two questions assess to what extent the
participant’s pain has changed their ability to (a) take
part in recreational, social, and family activities (Q2);
and (b) work (Q3). Both these questions are measured
on a scale from 0 to 10, with higher scores indicating
more extreme change.
For the last two questions, higher change scores are
meant to represent a higher negative change. However,
it is possible that some participants have misinter-
preted this, and have recorded a high score to indicate
a large positive change. We will therefore perform a
sensitivity analysis by redefining the outcome for par-
ticipants whose scores indicate they may have misin-
terpreted the intended direction of the questions relating
to change.
For participants with a score of 2 or less for Q1
(indicating very little interference in daily activities) and
a score of 8 or higher on either Q2 or Q3 (intending to
indicate an extreme negative change in their ability to
take part in social activities or to work), we will assume
the participant has misinterpreted the intended direction
of the scale for Q2 or Q3 (as it is inconsistent for the pain
to have had very little interference in daily activities, and
for there to have been an extreme negative change in the
participant’s ability to take part in activities or work). We
will therefore rescore Q2 or Q3 based on a reverse scale
(that is, a score of 10 will be rescored as 0, 9 will be
rescored as 1, and 8 will be rescored as 2). We will then
re-analyse the outcome using the same method as for the
main analysis.
Subgroup analyses
Subgroup analyses will be performed for the primary
outcome (CPG disability at 12 months). All subgroup
analyses will be performed using the same analysis
model as for the primary outcome, but will also include
the subgroup of interest and a treatment-by-subgroup
interaction. Interaction tests will be considered signifi-
cant at the 5% level. No correction will be made for mul-
tiple tests.
The following subgroups will be assessed:
Non-pain:
 Comorbidity (number of body systems affected): ≤3
versus >3 comorbidities (with chronic
musculoskeletal pain counting as a comorbidity)
 Living arrangements: living alone versus living with
others
 Baseline self-efficacy: PSEQ score 0 to 20 (not likely
to be confident) versus 21 to 39 (more likely to be
confident and to self manage) versus ≥40 (confident)
 Socioeconomic status (SES) (based on the Index of
Multiple Deprivation 2010, calculated from
participant postcodes via Geographical Information
Systems (GIS): lower social class (less than observed
median in data) versus higher social class (equal or
greater than observed median in data)
Pain-related:
 Pain duration: 0 to 12 months versus 13 months to
4 years versus 5 or more years
 Baseline pain intensity: CPG intensity score 0 to 3
(low) versus 4 to 7 (medium) versus 8 to 10 (high)
 Baseline pain-related disability: CPG disability score
0 to 3 (low) versus 4 to 7 (medium) versus 8 to 10
(high)
 Baseline depression: HADS depression score <11
versus ≥11
Analysis of secondary outcomes
CPG disability at 6 months
This outcome will be analysed using the same methods
as CPG disability at 12 months.
CPG pain intensity, HADS Anxiety, HADS Depression, and
HEIQ at 6 and 12 months
These outcomes will be analysed using the same methods
as CPG disability at 6 and 12 months.
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PSEQ at 6 and 12 months
These outcomes will be analysed using the same methods
as CPG disability at 6 and 12 months, except the individual
components of the PSEQ score at 12 weeks will also be in-
cluded in the imputation model (in addition to the PSEQ
score at baseline, 6, and 12 months).
CPAQ at 6 and 12 months
These outcomes will be analysed using the same
methods as CPG disability at 6 and 12 months, with the
exception of how CPAQ at baseline is included in the
MI model. We will include the individual questions for
CPAQ at 6 and 12 months in the imputation model, and
include the overall CPAQ score at baseline For partici-
pants who are missing CPAQ at baseline, we will use
mean imputation [33]. We chose this approach because
CPAQ is a composite of 20 questions including each of
these questions at each time point in the imputation
model would lead to 60 variables being included (20
questions at baseline, 20 at 6 months, and 20 at 12
months), which may cause problems [34]. Including the
overall CPAQ score at baseline rather than the 20 indi-
vidual questions would reduce the number of variables
from 60 to 41.
EQ-5D at 6 and 12 months
These outcomes will be analysed using the same analysis
model as the primary outcome (that is, a mixed-effects
linear regression model, with course as a random effect,
adjusted for site of recruitment, age, gender, HADS de-
pression score, and EQ-5D at baseline).
All participants who fully complete the EQ-5D score
at either 6 or 12 months will be included in the analysis.
MI will be used to account for participants who are
missing the outcome at either 6 or 12 months. The MI
strategy will be the same as that for the primary and
other secondary outcomes, except instead of imputing
the individual components of the EQ-5D score, we will
impute the whole score.
Census global health question at 6 and 12 months
These outcomes will be analysed using a mixed-effects
ordered logistic regression model, with ‘course’ as a ran-
dom effect. Site of recruitment, age, gender, HADS de-
pression score, and the outcome at baseline will be
included as fixed covariates.
All participants who completed the Census global
health question score at either 6 or 12 months will be
included in the analysis.
MI will be used to account for participants who are
missing the outcome at either 6 or 12 months. The MI
strategy will be the same as that for the primary and
other secondary outcomes, except we will impute the
whole score (as there are no individual components).
Total DDDs up to 12 months post-randomisation for
psychotropic drugs, drugs for pain, weak opioids, and
strong opioids
These outcomes will be analysed using a mixed-effects
linear regression model, with ‘course’ as a random effect.
Restricted maximum likelihood (REML) will be used.
The model will include site of recruitment, age, gender,
HADS depression score, and Total DDD in 3 months
before randomisation at baseline as covariates. All par-
ticipants who have data on Total DDD up to 12 months
post-randomisation will be included in the analysis. In
order to include participants with missing covariates in
the analysis, mean imputation will be used to account
for missing baseline covariates [33].
Proportion of participants using weak opioids and strong
opioids at 12 months post-randomisation
These outcomes will be analysed using a mixed-effects
logistic regression model, with ‘course’ as a random ef-
fect. The model will include site of recruitment, age,
gender, HADS depression score, and weak or strong
(depending on outcome) opioid use at baseline (defined
as a prescription for weak or strong) opioids in the 12
weeks before randomization) as covariates. All partici-
pants who have data on whether they had had a weak/
strong opioid prescription at 12 months will be included
in the analysis. Mean imputation will be used to account
for missing baseline covariates [33].
Adherence-adjusted analysis
As a secondary analysis, CPG disability, CPG pain inten-
sity, PSEQ, HADS anxiety, HADS depression, CPAQ,
HEIQ, and EQ-5D, all at 12 months will be re-analysed
to obtain a complier average causal effect of treatment
(CACE) [35,36]. This is because while ITT will give an
unbiased estimate of the effect of assigning treatment, it
may underestimate the effect of actually receiving the
treatment. An analysis using CACE will lead to an un-
biased estimate of receiving treatment.
We define ‘compliers’ as those who attend more than
half of the course (that is, those present for at least 12
of the 24 course components). The compliers can only
be observed in the intervention group, where an indi-
cator variable will indentify whether the individual
complied. The compliers’ class is unobserved in the control
group.
The analysis will be performed using the Stata com-
mand ivregress, with the option vce (cluster clustvar) to
account for clustering by course group. Randomisation
will be used as an instrumental variable for treatment
received. The main analysis will be adjusted for CPG
disability score at baseline, site of recruitment, age,
gender, and the HADS depression score at baseline.
Analyses will be performed using the same multiply
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imputed datasets as the primary analysis. The assump-
tions used for this analysis, as well as other adherence-
adjusted analyses to be performed, are listed in the
online appendix.
Additional file
Additional file 1: Methods used to calculate derived variables, and
more information on how adherence-adjusted analyses will be
performed.
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